Klinger Shannon Thyme, Chief Legal Officer at Moderna (MRNA), has demonstrated a clear selling bias in recent insider transactions, with $1.98 million in total sales outweighing $429,880 in purchases across 30 reported trades. The activity has been exclusively concentrated in Moderna shares, with the most significant transactions occurring in early March 2026. On March 2, Thyme sold $726,047 worth of MRNA stock while simultaneously acquiring shares worth $429,880 through market purchases, followed by an additional $329,691 sale on March 5. These transactions represent the largest dispositions in the filing period, continuing a pattern of net reduction in holdings that began with a $581,605 sale in December 2025.
The trading history shows intermittent smaller sales throughout late 2025 and early 2026, including multiple transactions under $10,000 in February 2026, suggesting a systematic approach to divesting positions rather than isolated large-scale moves. Notably, all purchases appear to be market acquisitions rather than option exercises, while sales have been executed at varying price points. The absence of any recent buys—with the last market purchase occurring on March 2, 2026—reinforces the overall disposition trend. The data reflects a consistent reduction in exposure to Moderna equity, with no trades reported in other securities.
AI-assisted summary